Acquired hemophilia successfully treated with recombinant factor VIIa: A case report
1 Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Isfahan, Iran.
2 Department of General Surgery, Isfahan University of Medical Sciences, Isfahan, Iran.
3 Family Medicine Department, Shahrekord University of Medical Sciences, Shahrekord, Iran.
4 Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Iran.
5 Department of Obstetrics and Gynecology, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Research Article
Open Access Research Journal of Biology and Pharmacy, 2024, 11(02), 031–035.
Article DOI: 10.53022/oarjbp.2024.11.2.0030
Publication history:
Received on 10 June 2024; revised on 24 July 2024; accepted on 27 July 2024
Abstract:
Acquired Hemophilia A (AHA) is a disorder characterized by the impaired clotting ability of the blood, primarily resulting from a deficiency in factor VIII, a crucial clotting protein. It is an infrequent disorder that affects a minority of individuals. This condition can pose a life-threatening risk, with reported mortality rates reaching as high as 22%. The diagnosis of AHA is challenging owing to its non-specific presentation and low prevalence rate. The primary objectives of treatment for AHA encompass the cessation and prevention of bleeding episodes, eradication of the inhibitor, and management of the underlying disease in secondary cases. This case report summarizes the successful treatment of a patient with AHA and major bleeding with the repeated use of prednisolone, recombinant factor VIIa, and rituximab.
Keywords:
Hemophilia A; Recombinant factor VIIa; Rituxima
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0